Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882889 | 0.92 | WDR5 (0.47) | KCNQ2NTRK1WDR5SMN1; SMN2GAA | |
| SCHEMBL4882866 | 0.76 | NTRK1 (0.48) | NTRK1LMNASMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL24516946 | 0.72 | TP53 (0.47) | WDR5LMNASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL4876069 | 0.70 | ALDH1A1 (0.43) | NTRK1SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL12839310 | 0.69 | CYP1A2 (0.43) | KCNQ2MAPK14LMNASMN1; SMN2GAA | |
| SCHEMBL10977876 | 0.66 | GAA (0.83) | SMN1; SMN2GAAALDH1A1RAB9A | |
| SCHEMBL9436258 | 0.66 | TGFBR1 (0.69) | MAPK14TGFBR1SMN1; SMN2CSNK1DCSNK1E | |
| SCHEMBL13200785 | 0.65 | MAPK14 (0.54) | NTRK1MAPK14LMNASMN1; SMN2GAA | |
| SCHEMBL1051059 | 0.65 | KCNH2 (0.59) | TGFBR1LMNAGAA | |
| SCHEMBL12952282 | 0.65 | KCNH2 (0.72) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-10-09 | — | — | US | claimed |
| EP-1698335-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DISEASE IN WHICH MITOCHONDRIAL BENZODIAZEPINE RECEPTOR PARTICIPATES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | claimed |
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1698335-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DISEASE IN WHICH MITOCHONDRIAL BENZODIAZEPINE RECEPTOR PARTICIPATES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | MTNR1A, GSR, NLN | KCNQ2 1443/4885NTRK1 492/4885MAPK14 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.